Oxford Biomedica plc (OXBDF) Q4 2025 Earnings Call March 26, 2026 9:00 AM EDT
Company Participants
Frank Mathias – CEO & Director
Sebastien Ribault – Chief Business Officer
Lucinda Crabtree – CFO & Director
Conference Call Participants
Charles Weston – RBC Capital Markets, Research Division
Zain Ebrahim – JPMorgan Chase & Co, Research Division
Kane Slutzkin – Deutsche Bank AG, Research Division
Julie Simmonds – Panmure Liberum Limited, Research Division
Miles Dixon – Peel Hunt LLP, Research Division
Presentation
Operator
Hello, and welcome to OXB 2025 Preliminary Results. We are joined today by Dr. Frank Mathias, Chief Executive Officer; Dr. Lucinda Crabtree, Chief Financial Officer; and Dr. Sebastien Ribault, Chief Business Officer. [Operator Instructions] I would now like to hand the call over to Dr. Frank Mathias. Please go ahead.
Frank Mathias
CEO & Director
Thank you so much for the introduction. Good morning to those in the U.S., and good afternoon to everyone else, and thank you for joining our OXB preliminary results briefing for the full year of 2025. Presenting alongside I just mentioned with me today is our Chief Financial Officer, Dr. Lucinda Crabtree; as well as our Chief Business Officer, Dr. Sebastien.
Next slide, please. Before we begin — sorry, one back — sorry. Before we begin, I will quickly run through today’s meeting agenda as seen now on the screen. We’ll begin with the business update, providing an overview of OXB’s key achievements over the period and highlighting the steps we have taken this year to further strengthen our position as a leading global cell and gene therapy CDMO. I will then hand over to Sebastien, who will provide an update on the strong commercial momentum we are seeing across the business and the positive fundamentals of the cell and gene therapy market. Lucy will then take us through the group financial performance in 2025 before handing back to me for closing remarks
